DHRS9 and neoplasm: As displayed in Table 2, high DHRS9 immunoexpression was remarkably connected to advanced pre-CCRT and post-CCRT tumor status (p = 0.032 and p < 0.001), post-CCRT lymph node involvement (p = 0.042), and vascular invasion (p = 0.005).